卵巢癌的诊断和治疗(医大讲课)课件

单击以编辑母版标题样式,单击以编辑母版文本样式,第二级,第三级,第四级,第五级,*,Diagnosis and Treatment of,Ovarian Cancer,Shen Keng,Department of OB/GYN,Peking Union Medical College Hospital,Diagnosis and Treatment of,1,Epidemiology and Genetic Factors,Ovarian cancer is the second most common gynecological malignancy, but the commonest malignancy of the female genital tract to result in death,Incidence: In general population lifetime risk for ovarian cancer in a women is roughly 1/70 or 1.4%.,Epidemiology and Genetic Facto,2,Epidemiology and Genetic Factors,The incidence in Asia, Africa and Latin America is lower than in Western countries.,The most common tumor type is epithelial (85%).,Epidemiology and Genetic Facto,3,卵巢癌的危险因素,年龄,危险因素,与子宫内膜、结肠、乳腺癌的关系,家庭史,生产史和激素水平,卵巢癌的危险因素年龄危险因素与子宫内膜、结肠、乳腺癌的关系家,4,Epidemiology and Genetic Factors,High risk factors:,1. More than 40yrs.,2. Caucasian race (white),3. Late menopause.,4. Infertility,5. Positive family history of CA ovary,6. BRCA gene,Epidemiology and Genetic Facto,5,Epidemiology and Genetic Factors,Family history is the strongest risk factor for ovarian cancer,Women with one affected first class relative: risk rate for ovarian cancer is 5%,Women with two affected first class relative: risk rate for ovarian cancer is 7%,A member of HOCS: risk rate for ovarian cancer is 20%-50%,BRCA1 &BRCA2 gene associated with HOCS,Epidemiology and Genetic Facto,6,Epidemiology and Genetic Factors,Prevention & protective factors for ovarian cancer appear to be conditions associated with fewer lifetime ovulations,1. Use of oral contraceptive pills,2. Shorter duration of reproductive years,3. Conditions of chronic anovulation,4. History of breastfeeding,5. Multiparity,Epidemiology and Genetic Facto,7,Histopathology,Epithelial ovarian cancer, usually classed simply as adenocarcinoma, include a number of specific histological types:,Serous adenocarcinoma,Muconous adenocarcinoma,Endometrioid adenocarcinoma,Malignant Brenner tumor (transitional cell),Clear cell adenocarcinoma,HistopathologyEpithelial ovari,8,Histopathology,Malignant Germ Cell Tumor of the Ovary include a number of specific histological types:,Dysgerminoma,Yolk-Sac Tumor (endodermal sinus tumor),Teratomas,Choriocarcinoma,Mixed germ cell tumor,HistopathologyMalignant Germ C,9,Histopathology,Malignant Tumor of the Gonadal stroma:,Granulosal-cell tumors,Adult type,Juvenile type,Sertoli-cell tumors,Leydig-cell tumors,Sertoli-Leydig-cell tumors,Sex cord tumor with annular tubules,HistopathologyMalignant Tumor,10,Spread of ovarian cancer,Local spread,Intra-abdominal spread,lymphatic spread,hemtogenous spread,Spread of ovarian cancerLocal,11,Symptoms,Symptoms,are most often,absent,with early stage ovarian cancer. When present, symptoms tend to be,nonspecific,GI tract complaints:,such as nausea, abdominal cramping, or change in bowel habits,are often the early symptoms of advanced stage disease. By this time, the disease may be widely disseminated throughout the peritoneal cavity,Abdominal distention,:,big mass, omental cake, ascites intestinal obstruction,SymptomsSymptoms are most ofte,12,Symptoms,Postmenopausal bleeding,may occur from endometrial hyperplasia stimulated by estrogen from a ovarian tumor.,Virilization,is found in 50% of patients who have an androgen-secreting Sertoli-Leydig-cell tumor.,Colicky pain,is associated with torsion of a mobile ovarian tumor.,Constant pain,may be experienced with the distention of hemorrhage into a tumor,SymptomsPostmenopausal bleedin,13,Physical examination,Fixed, bilateral pelvic masses,Abdominal mass: omental cake, big ovarian tumor,Abdominal percussion: ascites,A nodular tumor in POD,Pleural effusion,Meiges syndrome consists of ascites and hydrothorax associated with fibroma and thecoma.,Physical examinationFixed, bil,14,Preoperative workup,Pap smear,(f) D&C,Tumor makers:,CA125, CEA, HCG, AFP, LDH,Chest film to look for lung metastasis and pleural effusion,Preoperative workupPap smear,15,Preoperative workup,Barium enema to evaluate the lower GI tract,Plain film of the abdomen to identify intestinal obstruction,IVP to assess the urinary system,USG, CT scan or MRI to determinate the anatomy relationship between the ovarian cancer and pelvic organs,Preoperative workupBarium enem,16,卵巢癌的MRI,Courtesy of Barry N. Siskind, MD, The Graduate Hospital Imaging Center, Philadelphia, PA, USA,子宫,卵巢 肿块,直肠,卵巢癌的MRICourtesy of Barry N. Si,17,Preoperative workup,Peritoneocentesis for reliving abdominal distention and cytology examination.,Laparoscopy can be used to obtained pathological diagnosis of ovarian cancer preoperatively,Preoperative workupPeritoneoce,18,The role of Surgery in the management of ovarian cancer,Diagnostic,Establish diagnosis and determine histology and grade of the tumor Surgical staging Reassessment Laparotomy,Therapeutic,Primary cytoredution Secondary cytoreduction Provision of intravenous and intraperitonel access,Palliative,Reduction of tumor bulk, Relieve gastrointestinal obstruction,The role of Surgery in the man,19,Surgeries for ovarian cancer,Comprehensive staging laparotomy,Restaging laparotomy,Primary cytoreductive surgery,Interval debulking,Second-look laparotomy,Second debulking,(Recytoreductive surgery),Surgeries for ovarian cancerCo,20,Standard procedure of cytoreductive surgery for ovarian cancer,Longitudinal incision,Abdominal fluid for cytology,Exploration,Omentectomy,Total hysterectomy,Bilateral salpingo-oohporectomy,Para-aortic and pelvic lymphadenectomy,Low anterior resection of colon,Appendectomy,Standard procedure of cytoredu,21,卵巢癌的临床分期,卵巢癌的临床分期,22,卵巢癌I期和II期,Ia,期,Ic,期,腹水,阳性,或,Ib,期,I期,II,期,IIa,期,IIb,期,IIc,期,卵巢癌I期和II期Ia期 Ic 期腹水阳性 或Ib期I期I,23,卵巢癌III期和IV期,Beecham Sevigne,M,閙,ento de Stadification des Principales Tumeurs Solides,III期,种植性肝转移,腹腔腹膜转移,肝实质性转移,恶性胸膜细胞,前锁骨淋巴结,IV期,卵巢癌III期和IV期Beecham Sevigne, M閙,24,卵巢癌的诊断和治疗(医大讲课)课件,25,卵巢癌的诊断和治疗(医大讲课)课件,26,卵巢癌的诊断和治疗(医大讲课)课件,27,卵巢癌的诊断和治疗(医大讲课)课件,28,卵巢癌的诊断和治疗(医大讲课)课件,29,卵巢癌的诊断和治疗(医大讲课)课件,30,卵巢癌的治疗: 手术 (I),DeVita et al.,Cancer: Principles & Practice of Oncology,.1993,全腹腔探查,和活检,网膜,几乎所有的病人进,行全子宫、双侧输,卵管及网膜切除术,卵巢癌的治疗: 手术 (I)DeVita et al. Ca,31,卵巢癌的诊断和治疗(医大讲课)课件,32,卵巢癌的诊断和治疗(医大讲课)课件,33,卵巢癌的诊断和治疗(医大讲课)课件,34,Lymph nodes metastasis and retroperitonal lymphadenectomy in ovarian cancer,Lymphatic pathway is an important route of metastasis in ovarian cancer.,The overall incidence of retroperitoneal positive nodes 54.3%,The incidence of positive pelvic nodes 46.7% positive para-aortic nodes 37.5%,Both aortic and pelvic nodes positive 48.7%,Lymph nodes metastasis and ret,35,卵巢癌的诊断和治疗(医大讲课)课件,36,卵巢癌的诊断和治疗(医大讲课)课件,37,卵巢癌的诊断和治疗(医大讲课)课件,38,卵巢癌的诊断和治疗(医大讲课)课件,39,Intestinal metastasis and operation in ovarian cancer,Rectosigmoid involved 95.2%,Metastasis to small bowel 41.9%,Superficial and serosal invasion 64.5%,Complete or optimal resection 74.2%,resection of the bowel 31.2%,Colostomy 9.8%,27.4% survival with mean survival time 30.3 months,Intestinal metastasis and oper,40,卵巢癌的诊断和治疗(医大讲课)课件,41,Conservative surgery in ovarian cancer,Germ cell tumor (any stage),Stage I grade I granulosal cell tumor,For epithelial cancer :,1. Young patient and desire of reproduction,2 Stage Ia,3. Grade 1,4. Capsule intake,5. No adhesion,6. Peritoneal cytology negative,7. Multiple biopsies of high risk negative,8. Follow up available,Conservative surgery in ovaria,42,Management of Ovarian Cancer,Early disease,Stage IA/B grade I/II,exploratory operation; conservative resection,preserve fertility in bilateral borderline tumours,adjuvant therapy unproven,Unfavourable type,poorly differentiated clear cell tumours,capsule penetration,ruptured capsule,positive washings,stage II: standard operation + adjuvant therapy,Management of Ovarian CancerEa,43,早期卵巢癌的化疗,FIGO I，II期卵巢癌,“预后好”的患者90%以上可长期无瘤存活，而且不需要辅助化疗。,有高危因素的患者，30%-40%有复发的危险，25%-30%在首次手术后5年内死亡。,与复发有关的高危因素,：,（1）包膜破裂 （2）肿瘤表面生长 （3）低分化（G3）（4）与周围组织粘连 （5）透明细胞癌 （6）腹腔冲洗液阳性 （7）卵巢癌外转移,早期卵巢癌的化疗FIGO I，II期卵巢癌,44,Management of Ovarian Cancer,Advanced stage disease,Stage III/IV,Primary cytoreductive surgery / interval debulking,Obtained optimal debulkung (residual tumor 6 months)-secondary debunking following chemotherapy,Palliative treatment (Radiotherapy, immunotherapy) unproven,Management of Ovarian Cancer,45,Chemotherapy in ovarian cancer,First line chemotherapy for epithelial ovarian cancer,CHexUP and Thio-Tepa protocol ( 1982-1985),PAC or PC (1986-1990),DDP, 5-FU, Ara-c, Bleomycin, CTX. IP & IV Combination (1991-1994),Taxol, DDP/Carpa (1995-2000),Weekly taxol /Carpa(2000-),Chemotherapy in ovarian cancer,46,Combination Chemotherapy,Cisplatin,acts by binding to DNA and producing cross-links and DNA adducts.,Cisplatin,is a very effective drug for ovarian cancer.,Important side effects,include severe nausea and vomiting, dose-related nephrotoxicity, ototoxicity, peripheral nerutoxicity and myelosuppresion,Combination ChemotherapyCispla,47,Combination Chemotherapy,The mechanism of action of,carboplatin,is the same as that of cisplatin, the side effects, however, differ greatly.,The most important side effect is thrombocytopenia. Leukopenia and anemia also occur but are less severe.,Neurotoxicity and nephrotoxicity are less severe with carboplatin than with cisplatin,Other important side effect include alopecia and mucositis.,Combination ChemotherapyThe me,48,Combination Chemotherapy,Paclitaxel,acts as a mitotic spindle poison.,Paclitaxel,is also a very effective drug for ovarian cancer at the present time,Some patients exhibit hypersensitivity to paclitaxel.,Other side effect include myelosuppression , nerotoxicity, mucositis, diarrhea, alopcia nausea and vomiting,Combination ChemotherapyPaclit,49,卵巢上皮癌的化疗,铂基础治疗方案通常联合:,紫杉醇,环磷酰胺,阿霉素,通常需要间隔3- 4周至少6个周期的治疗,卵巢上皮癌的化疗铂基础治疗方案通常联合:,50,晚期卵巢癌的化疗,一线治疗,国内,顺铂+环磷酰胺(PC),顺铂+阿霉素+环磷酰胺(PAC),国外,泰素顺铂,泰素卡铂,泰素每周疗法,晚期卵巢癌的化疗一线治疗,51,Combination Chemotherapy,Combination chemotherapy,most often is used as postoperative treatment for advanced epithelial ovarian cancer. Combination chemotherapy with six courses of,cisplatin,or,carboplatin,plus,paclitaxel,is the treatment of choice for patients with advanced disease.,Courses,are given every 3 to 4 weeks with monitoring of tumor status by physical examination. CA125 levels ,and imaging studies if appropriate,Combination ChemotherapyCombin,52,卵巢癌病人化疗存活率,McGuire WP et al.,N Engl J Med.,1996,卵巢癌病人化疗存活率McGuire WP et al. N,53,Post-Therapy Surveillance,Follow-up after therapy in ovarian cancer is poorly defined.,At the present time there is no definitive test for detecting the presence of microscopic recurrent epithelial ovarian cancer,For this reason there remains significant controversy as to what constitutes optimal posttherapy surveillance.,Post-Therapy SurveillanceFollo,54,Post-Therapy Surveillance,Screening modalities:,1.,Pelvic Examination,2.,CA 125,(44% sensitivity, 96% specificity, 65% accuracy),3.,Ultrasound,(20%-89% sensitivity, 75%-100% specificity),4.,Second-look laparotomy,5.,CT scan,(44% sensitivity, 86% specificity, 63% accuracy),6.,MIR imaging.,6.,Position emission tomography (PET),(83% sensitivity, 80% specificity, 82% accuracy),Post-Therapy SurveillanceScree,55,卵巢癌的诊断和治疗(医大讲课)课件,56,卵巢癌的诊断和治疗(医大讲课)课件,57,卵巢癌的诊断和治疗(医大讲课)课件,58,卵巢癌复发的诊断和治疗,首次的规范化治疗,(理想的肿瘤细胞减灭术加上以足够疗程的铂类和/或紫杉醇为基础的联合化疗),70%-80%的患者可获得临床完全缓解.,60%-70%的患者最终还会复发.,对卵巢癌复发的诊断和治疗是卵巢癌治疗中最为棘手的问题.,怎样合理处理复发性卵巢癌意见尚不统一,卵巢癌复发的诊断和治疗首次的规范化治疗(理想的肿瘤细胞减灭术,59,卵巢癌的复发,类型 (1),化疗敏感型卵巢癌:,定义为对初期以铂类药物为基础的治疗有明确反应,且已经达到临床缓解,停用化疗6个月以上,病灶复发.,卵巢癌的复发类型 (1)化疗敏感型卵巢癌:,60,卵巢癌的复发,类型 (2),化疗耐药型卵巢癌:,定义为患者对初期的化疗有反应,但在完成化疗相对短的时间内证实复发,一般认为,完成化疗后6个月内的复发,应考虑为铂类药物耐药,卵巢癌的复发类型 (2)化疗耐药型卵巢癌:,61,卵巢癌的复发,类型(3),顽固性卵巢癌:,是指在初期化疗时对化疗有反应,或,明显反应的患者中发现有残余病灶,例如:,“,二探”阳性者.,卵巢癌的复发类型(3)顽固性卵巢癌:,62,卵巢癌的复发,类型 (4),难治性卵巢癌:,是指对化疗没有产生最小有效反应的患者,包括在初始化疗期间,肿瘤稳定或肿瘤进展者,大约发生于20%的患者. 这类患者对二线化疗的有效反应率最低.,卵巢癌的复发类型 (4)难治性卵巢癌:,63,卵巢癌复发的治疗,治疗前的准备:,详细复习病史包括,:,(1)手术分期. (2)组织学类型和分级. (3)手术的彻底性. (4)和残余瘤的大小及部位. (5)术后化疗的方案,途径,疗程,疗效. (6)停用化疗的时间. (7)出现复发的时间等.,对复发性卵巢癌进行定性、分型、定位分析,对患者的生活状态(PS)进行评分,对患者重要器官的功能进行评估.,卵巢癌复发的治疗治疗前的准备:,64,目前观点认为:,对于复发性卵巢癌的治疗目的一般是趋于保守性的, 因此在选择,复发,性,卵巢癌,治,疗方案时,对所选择方案的预期毒性作用及其对整个生活质量的影响都应该加以重点考虑.,目前观点认为: 对于复,65,复发性卵巢癌的手术治疗,手术对复发性卵巢癌的治疗价值尚未确定, 手术的指征和时机还存在一些争论.,复发性卵巢癌的手术治疗主要用于三个方面:,1.解除肠梗阻,2.12个月复发灶的减灭.,3.切除孤立的复发灶.,对晚期复发卵巢癌是先手术还是先化疗仍有争议.,复发性卵巢癌的手术治疗手术对复发性卵巢癌的治疗价值尚未确定,66,Chemotherapy in Ovarian Cancer,Second line chemotherapy for epithelial ovarian cancer,Patients with persistent or recurrent diseases should be treated with second line chemotherapy.,Unfortunately, response rates for second line chemotherapy are only 10% to 30%.,Regarding of the approach, second line chemotherapy for persistent or recurrent ovarian cancer is not curative.,Chemotherapy in Ovarian Cancer,67,Second line chemotherapy for epithelial ovarian cancer,Depending on the initial chemotherapy, second line chemotherapy may include:,Topotecan,Paclitaxel,Platinum,Ifosfamide,Taxotere,Hexamethylmelamine,Combination Chemotherapy,Second line chemotherapy for e,68,对复发卵巢癌有效的新药,对复发卵巢癌有效的新药,69,Survival,Early-stage disease,Five year survival rate for patients with stage I or stage II disease are 80% to 100, depending on the tumor grade,Advanced disease,Five year survival rate for patients with stage IIIa is 30% to 40%,Five year survival rate for patients with stage IIIb is 20%,Five year survival rate for patients with stage IIIc or IV is 5%,Recurrent disease,Five year survival rate for patients with negative SLL is 50%,Five year survival rate for patients with microscopic disease is 35%,Five year survival rate for patients with macroscopic disease is 5%,SurvivalEarly-stage disease,70,Malignant Germ Cell Tumor of the Ovary,Twenty percent to 25% of all malignant tumor of the ovary are of germ cell origin.,In the first decades of life, 70% of ovarian tumors are of germ cell origin and one third are malignant,Germ cell tumors are quite rare after the third decades of life.,Malignant Germ Cell Tumor of t,71,1.Malignant germ cell tumor of the ovary is very sensitive to the chemotherapy. Chemotherapy has been a very important treatment for this kind ovarian tumor.,2.Chemotherapy has improved the survival of patients with Malignant germ cell tumor of the ovary dramatically. Survival rate has been increased from 10% to 90%,3.Reproductive function can be preserved for any stage patients with malignant germ cell tumor of the ovary,Malignant Germ Cell Tumor of the Ovary,1.Malignant germ cell tumor of,72,Management of malignant germ cell tumor of the ovary,Primary treatment is surgical.,Unilateral oophorectomy with preserved reproductive function is considered.,PVB and PEB chemotherapy are the treatment of choice for patients with MGCT postoperatively,Courses of chemotherapy are depending on the high risk factors of the tumor,and tumor maker levels,Management of malignant germ c,73,Sex cord stromal tumors,Ovarian sex cord-stromal tumor account for less than 5%.,It may occur at any age, although the age of peak incidence for granular cell tumors is in the postmenopausal years.,No standard therapy exists.,Lower malignant potential and late recurrence,Sex cord stromal tumorsOvarian,74,Sex cord stromal tumors,Surgery remains cornerstone of treatment for patients with ovarian sex cord stromal tumors.,95% of the tumor are unilateral, 95% are confined to the ovary.,Unilateral salpingo-oophorectomy seems to appropriate treatment for young patients with stage Ia disease.,THBSO is considered standard surgery for old patients and advanced stage diseases.,Sex cord stromal tumorsSurgery,75,Sex cord stromal tumors,PVB chemotherapy is the treatment of choice for selected patient with sex cord stromal tumor after surgical treatment.,Long term follow-up should be considered for this kind of tumor because of late recurrence.,The 10 year survival rate is 90%, and the 20 year survival rate drop to 75%.,Sex cord stromal tumorsPVB che,76,Sex cord stromal tumors,Prognostic factors,Stage(extraovary metastasis),Tumor size,Histologic type,Mitotic count,Atypia,DNA ploidy,(associated with other adverse,histolopathologic parameters),High stage, vascular invasion, nuclear atypia,high mitotic,activity plus aneuploidy,poor prognosis,Sex cord stromal tumors Progno,77,卵巢癌的诊断和治疗(医大讲课)课件,78,卵巢癌的诊断和治疗(医大讲课)课件,79,